Avalanche Biotechnologies fell 56 percent, but CEO Thomas Chalberg declined to say whether he would buy more shares.» Read More
Foundation Medicine CEO Michael Pellini tells CNBC, "It's an important day for patients battling cancer."
*Foundation Medicine jumps; Roche to take majority stake. NEW YORK, Jan 12- U.S. stock index futures rose on Monday, after a two-day decline pushed the S&P 500 back into negative territory for the year, as investors anticipated the start of the corporate earnings season. *Alcoa is scheduled to post quarterly earnings after the closing bell, with financials JPMorgan...
ZURICH/ LOS ANGELES Jan 12- Roche Holding will acquire a majority stake in molecular and genomic analysis business Foundation Medicine, it said on Monday, signalling its determination to expand in cancer immunotherapy by paying a hefty mark-up on the U.S. company's current price. The deal will help the world's largest maker of cancer drugs push ahead in...
CNBC's Meg Tirrell, and Michael Pellini, Foundation Medicine president & CEO, discuss the benefits of Roche's majority stake in Foundation Medicine.
Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.
ZURICH/ LOS ANGELES Jan 12- Roche Holding will acquire a majority stake in molecular and genomic analysis firm Foundation Medicine Inc for up to $1.18 billion, it said on Monday, in a move to bolster the Swiss drugmaker's personalised cancer treatments. The drugmaker said it will tender for about 15.6 million Foundation shares at $50 a share, worth up to about $780...
Swiss drug maker Roche plans to acquire a majority stake in Foundation Medicine by buying a combination of outstanding and newly issued shares.
The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.
European shares closed mixed on Monday, with Greece struck by renewed political uncertainty after its politicians failed to agree on a new president.
European shares closed mixed on Friday, with Italian banking stocks and the health care sector weighing on wider benchmarks.
The health-care sector tends to outperform the overall market during flu season. Who else stands to gain?
There are few new cancer drugs to treat kids, and not much research is being done.
Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.
The U.S. FDA has revoked a tentative approval for India's Ranbaxy to make a cheap copy of AstraZeneca's heartburn drug Nexium.
Alibaba muscled ahead of Wal-Mart by one important measure, when its market valuation surpassed the retailer by revenues. The Financial Times reports.
Drugmakers are racing to develop vaccines and drugs to address Ebola, betting that governments and aid groups will foot the bill.
European shares closed lower on Thursday after trimming losses, tracking U.S. markets which partially recovered after visiting correction territory.
Roche reported third quarter sales of 11.78 billion Swiss francs ($12.29 billion) on Thursday, above analysts' forecasts of 11.58 billion Swiss francs in a Reuters poll.
Severin Schwan, CEO of Roche Group, says the company's "fundamental strategy" has not changed and is looking at "targeted" M&A deals.
Severin Schwan, CEO of Roche Group, says the world was surprised by the "magnitude" of the Ebola outbreak.